GlaxoSmithKline plans to co-develop a rheumatoid arthritis drug being tested by Human Genome Sciences. GSK said it would exercise its co-development option under a 1996 agreement between the two firms, with both companies sharing the costs of late-stage clinical trials and marketing costs if the drug is commercialized.

Related Summaries